SCHEMBL3262883

SCHEMBL3262883

C#CCNNC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30303131 0.77
Hydrochloric Acid SCHEMBL29141671 0.77 MAOB (0.31)
SCHEMBL15336897 0.73
SCHEMBL79182 0.72
SCHEMBL12501184 0.72
SCHEMBL4742935 0.72 CA2 (0.37)
SCHEMBL31159539 0.71 HDAC1 (0.50)
SCHEMBL9244287 0.69 TPMT (0.41)
SCHEMBL2023689 0.69
SCHEMBL1512247 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090017015-A1 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders HUGHES THOMAS EDWARD 2009-01-15 US claimed
US-20070110715-A1 Treatment of alzheimer's disease ARES TRADING S.A. (CH) 2007-05-17 US claimed
EP-1732550-A2 DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS Novartis AG (CH) 2006-12-20 EP claimed
EP-1620124-A2 IFN-BETA ALONE OR IN COMBINATION WITH OTHER MEDICAMENTS FOR TREATING ALZHEIMER'S DISEASE AND DEMENS DISORDERS ARES TRADING S.A. (CH) 2006-02-01 EP claimed
WO-2005079795-A2 DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS NOVARTIS AG (CH) 2005-09-01 WO claimed
WO-2004082706-A2 IFN-BETA ALONE OR IN COMBINATION WITH OTHER MEDICAMENTS FOR TREATING ALZHEIMER'S DISEASE AND DEMENS DISORDERS ARES TRADING S.A. (CH) 2004-09-30 WO claimed
WO-2021002735-A1 CELL SURFACE ANTIGEN OF T CELL AND VARIOUS USES THEREOF 주식회사 굳티셀 2021-01-07 WO disclosed
US-20100160408-A1 VILDAGLIPTIN FOR TREATING GENERAL PERIPHERAL NEUROPATHIES NOVARTIS AG (CH) 2010-06-24 US disclosed
US-20090017015-A1 Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders HUGHES THOMAS EDWARD 2009-01-15 US disclosed
US-20070110715-A1 Treatment of alzheimer's disease ARES TRADING S.A. (CH) 2007-05-17 US disclosed
EP-1732550-A2 DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS Novartis AG (CH) 2006-12-20 EP disclosed
EP-1620124-A2 IFN-BETA ALONE OR IN COMBINATION WITH OTHER MEDICAMENTS FOR TREATING ALZHEIMER'S DISEASE AND DEMENS DISORDERS ARES TRADING S.A. (CH) 2006-02-01 EP disclosed
WO-2005079795-A2 DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS NOVARTIS AG (CH) 2005-09-01 WO disclosed
US-5488054-A TREATMENT OF RESTENOSIS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-30 US disclosed
US-5486522-A Carbamates of rapamycin AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-23 US disclosed
US-5486524-A RESTENOSIS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-23 US disclosed
US-5486523-A ANTIINFLAMMATORY AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-23 US disclosed
US-5484791-A TREATING PULMONARY INFLAMMATION AMERICAN HOME PRODUCTS CORPORATION 1996-01-16 US disclosed
US-5484790-A IMMUNOSUPPRESSANT IN TRANSPLANTS OR GRAFTS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-16 US disclosed
US-5480988-A USEFUL AS AN IMMUNOSUPPRESSANT, ANTIINFLAMMATORY AGENT, FUNGICIDE, ANTIGROWTH AGENT OR ANTITUMOR AGENT AMERICAN HOME PRODUCTS CORPORATION (US) 1996-01-02 US disclosed